Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07085611 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neutralizing Power of Serum Antibodies - 2

Study acronym: PNAS-2
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jul 11, 2030 to Aug 22, 2030v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 31, 2025 to Aug 22, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.
Trial Details
NCT Number NCT07085611
Lead Sponsor Centre Hospitalier Régional d'Orléans
Conditions
(from sponsor)		 COVID-19, SARS-CoV-2 Viraemia, Monkey Pox, Vaccination, Serum, Mucosal Immunity
Related terms COVID-19, Mpox, Monkeypox
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov